2754. Delafloxacin and Comparator Fluoroquinolone In Vitro Resistance Trends in Isolates from Skin and Skin Structure Infections in the USA (2017–2022)

BACKGROUND: Delafloxacin (DLX) is a broad-spectrum fluoroquinolone antibacterial approved in the USA in 2017 for treatment of acute bacterial skin and skin structure infection (ABSSSI). DLX is indicated to treat ABSSSI caused by multiple pathogens, including Staphylococcus aureus (methicillin-resist...

Descripción completa

Detalles Bibliográficos
Autores principales: Carvalhaes, Cecilia G, Shortridge, Dee, Duncan, Leonard R, Huband, Mike, Castanheira, Mariana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677959/
http://dx.doi.org/10.1093/ofid/ofad500.2365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677959/
http://dx.doi.org/10.1093/ofid/ofad500.2365

Ejemplares similares